Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (4383)	7/31/2001 11:14:11 PM
From: hmpa	Respond to of 52153

Since Novartis is the marketer, don't they have a blanket DEA quota for any and all varieties of methylphenidate (then CELG product will fall under it)?

To: Miljenko Zuanic who wrote (4383)	7/31/2001 11:25:07 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Thanks, Miljenko - I didn't know that. Any chance Novartis could "donate" some of their Ritalin quota? (I would guess not). October (10 months) would be pretty quick in the current FDA environment but maybe the company knew something when they talked about a third quarter approval target. Realistically though, it looks to me like '03 would be more likely for sales because of the DEA quota issue. I suppose they might get a milestone from Novartis on approval though, even if no sales in '02. Peter